Correction to: Scientific Reports https://doi.org/10.1038/s41598-018-37710-4, published online 30 January 2019


This Article contains an error in the title of Table 3.


“SERT occupancy (= percentage of decrease in specific over non-specific binding due to treatment) in different brain regions after treatment with escitalopram in patients with TS + OCD and pure OCD (n = 13) depending on quantification procedure.”


should read:


“SERT occupancy (= percentage of decrease in specific over non-specific binding due to treatment) in different brain regions after treatment with escitalopram in patients with TS + OCD (n = 8) depending on quantification procedure.”


In addition, the following text in the Results section contains typographical errors:


“Treatment with escitalopram in patients with TS + OCD and pure OCD (n = 13) resulted in a significant reduction of SERT binding in all investigated brain areas including caudate, putamen, thalamus, hypothalamus, midbrain, pons, and mesial temporal cortex (p values between 0.0409 and < 0.0001 depending on the brain region) with differences ranging from 19 to 78% (for further details see Table 3, and Figs. 1, 2). Thus, treatment with escitalopram resulted in a much larger difference in SERT binding compared to the differences detected between untreated patients (with TS + OCD and OCD) and healthy controls at baseline (range 8–11%, for further details see Table 2).”


should read:


“Treatment with escitalopram in patients with TS + OCD (n = 8) resulted in a significant reduction of SERT binding in all investigated brain areas including caudate, putamen, thalamus, hypothalamus, midbrain, pons, and mesial temporal cortex (p values between 0.0409 and < 0.0001 depending on the brain region) with differences ranging from 19 to 79% (for further details see Table 3, and Figs. 1, 2). Thus, treatment with escitalopram resulted in a much larger difference in SERT binding compared to the differences detected between untreated patients (with TS + OCD) and healthy controls at baseline (range 8–11%, for further details see Table 2).”